Safety and Tolerability of Nicotinamide Riboside in Heart Failure

The ChromaDex Research Communications Initiative is pleased to share a summary of a new study on Nicotinamide Riboside (NR) supplementation in Stage C heart failure patients. This study builds on the 2020 Zhou et al. study that showed that boosting Nicotinamide Adenine Dinucleotide (NAD+) with NR can improve peripheral blood mononuclear cell (PBMC) mitochondrial respiration and may have anti-inflammatory effects in Stage D heart failure patients.

We continue to keep our fingers on the pulse of NAD+ and NR supplementation as they correlate to real-world health outcomes and further the NAD+ dialogue. 

STUDY LINK & SUMMARY:

Dennis Wang, MD, PhD, University of Washington. “Safety and Tolerability of Nicotinamide Riboside in Heart Failure with Reduced Ejection Fraction.” Journal of the American College of Cardiology (JACC): Basic to Translational Science (Impact Factor: 9.531)

TAKEAWAYS:

This study demonstrated that high-dose NR is safe and well tolerated. It approximately doubled whole blood NAD+ levels, and increased white blood cell mitochondrial respiratory function and decreased expression of inflammatory markers, such as NLRP3.

This data suggests that NR may have therapeutic potential in heart failure and warrants additional research on its use as a potential therapeutic strategy.

KEY FINDINGS:

  • This study builds upon the findings from the pilot study by Zhou et al., 2020, which demonstrated oral supplementation of NR in Stage D heart failure patients increased whole blood NAD+ levels, improved white blood cell mitochondrial respiration, and significantly reduced inflammation.
  • It is important to note that this is the first study to investigate the safety and tolerability of NR in a randomized, placebo-controlled trial of patients with heart failure, paving the path for future clinical research.
  • As stated by the authors, determining the safety and tolerability of NR in patients with heart failure was a crucial translational step before investigating its effects on clinically relevant, surrogate endpoints and inflammation in larger studies.
  • The results of this study reinforce and are consistent with findings from previous preclinical and clinical research demonstrating NR has beneficial effects in heart failure.
  • Overall, this data suggests NR may support heart health, and warrants additional research on its use as a potential therapeutic strategy.

VIEW THE STUDY HERE